Login / Signup

Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma.

Kandice A KapinosEllen HuJigar TrivediPraveen Ramakrishnan GeethakumariAnkit Kansagra
Published in: Cancer control : journal of the Moffitt Cancer Center (2023)
These findings hinge on the assumption of longer-term survival but suggest that the use of CAR-T therapy is approaching standard ICER thresholds.
Keyphrases
  • multiple myeloma
  • cell therapy
  • single cell
  • preterm infants
  • cancer therapy
  • gestational age
  • stem cells
  • preterm birth
  • replacement therapy